Lymphoma News and Research

RSS

Lymphoma is cancer that begins in cells of the immune system. There are two basic categories of lymphomas. One kind is Hodgkin lymphoma, which is marked by the presence of a type of cell called the Reed-Sternberg cell. The other category is non-Hodgkin lymphomas, which includes a large, diverse group of cancers of immune system cells. Non-Hodgkin lymphomas can be further divided into cancers that have an indolent (slow-growing) course and those that have an aggressive (fast-growing) course. These subtypes behave and respond to treatment differently. Both Hodgkin and non-Hodgkin lymphomas can occur in children and adults, and prognosis and treatment depend on the stage and the type of cancer.

Merck presents KEYNOTE-057 trial results for patients with high-risk non-muscle invasive bladder cancer

Merck, known as MSD outside the United States and Canada, today announced the first presentation of results from an interim analysis of KEYNOTE-057, a Phase 2 trial evaluating KEYTRUDA, Merck's anti-PD-1 therapy, for previously treated patients with high-risk non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ or CIS plus papillary disease (Cohort A).

22 Oct 2018

FDA approves update to Rituxan label to include information on treatment of rare forms of vasculitis

Genentech, a member of the Roche Group, announced today that the U.S. Food and Drug Administration has approved an update to the Rituxan® (rituximab) label to include information on follow up treatment of adult patients with Granulomatosis with Polyangiitis and Microscopic Polyangiitis who have achieved disease control with induction treatment.

22 Oct 2018

Study highlights existence of barriers to early clinical trial access for adolescents and young adults

Young cancer patients at the crossroads of childhood and adulthood seem to be stuck in a treatment impasse. A study to be presented at the ESMO 2018 Congress in Munich, has highlighted the existence of barriers to the inclusion of 12 to 25-year-olds in both adult and pediatric early phase clinical trials, suggesting a need for more tailored approaches to give this patient population better access to therapeutic innovation.

22 Oct 2018

Takeda announces positive Phase 3 ALTA-1L data in first-line therapy for advanced ALK+ NSCLC

Takeda Pharmaceutical Company Limited today announced that intracranial efficacy data from the Phase 3 ALTA-1L (ALK in Lung Cancer Trial of BrigAtinib in 1st Line) trial showed improved intracranial progression-free survival (PFS) and intracranial objective response rate (ORR) with ALUNBRIG (brigatinib) compared to crizotinib among anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer (NSCLC) patients.

22 Oct 2018

Survey finds high prevalence of HTLV-1 infection among teens and adults in Gabon

A study published in PLOS Neglected Tropical Diseases, by Mirdad Kazanji, of the Centre International de Recherches Medicales de Franceville in Gabon, and the Institut Pasteur de la Guyane in French Guiana, suggests that 30 years after the first epidemiological survey of the seroprevalence of Human T-cell lymphotropic virus type 1 (HTLV-1) infections in Gabon, the country remains highly endemic, with a seroprevalence of 7.3%.

19 Oct 2018

Women not warned about cancer associated with breast implants

Breast surgeons across the UK must ensure women are aware of BIA-ALCL, a non-Hodgkin’s lymphoma (a rare form of cancer) that is associated with implants; and more responsibility must be taken to diagnose and report cases, surgeons attending the 2018 London Breast Meeting have warned.

17 Oct 2018

New blood test for pediatric brain tumor patients offers safer approach than surgical biopsies

A new blood test for children with brain tumors offers a safer approach than surgical biopsies and may allow doctors to measure the effectiveness of treatment even before changes are identified on scans, according to research led by UCSF Benioff Children’s Hospitals and Children’s National Health System.

16 Oct 2018

Phase 2 results on tazemetostat EZH2 inhibitor to be presented at ESMO 2018

Epizyme, Inc., a clinical-stage company developing novel epigenetic therapies, announced today that updated efficacy and safety data from the fully enrolled cohort of epithelioid sarcoma (ES) patients in its ongoing Phase 2 trial of tazemetostat will be presented in a poster discussion session at the European Society for Medical Oncology (ESMO) 2018 Congress to be held October 19-23 in Munich, Germany.

10 Oct 2018

'Supercharged' immune cells could help fight cancer

A type of 'supercharged' immune cell could be mass-produced to help fight cancer.

9 Oct 2018

NCCN adds COPIKTRA capsules to NCCN Guidelines for follicular lymphoma

Verastem, Inc., focused on developing and commercializing medicines to improve the survival and quality of life of cancer patients, today announced that the National Comprehensive Cancer Network added COPIKTRA (duvelisib) capsules to the Clinical Practice Guidelines in Oncology (NCCN Guidelines) for follicular lymphoma.

8 Oct 2018

Researchers caution that expediting HLH treatment may miss underlying cancers

Physicians who specialize in a devastating and aggressive immune disorder called hemophagocytic lymphohistiocytosis report in a new study that extra care should be taken to ensure an HLH diagnosis doesn't obscure possible underlying cancers.

1 Oct 2018

Phase 3 ECHELON-2 clinical trial evaluating ADCETRIS plus CHP meets primary endpoint

Seattle Genetics, Inc. and Takeda Pharmaceutical Company Limited announced today that the phase 3 ECHELON-2 clinical trial met its primary endpoint.

1 Oct 2018

Cosmetic surgery providers' websites offer incomplete information to breast augmentation customers

Research at Brighton and Sussex Medical School has found that websites by cosmetic surgery providers offer incomplete information to perspective patients.

28 Sep 2018

Loyola announces plans to produce CAR-T cells for treating cancer

Loyola University Chicago and Loyola Medicine have announced plans to become the first Chicago center to produce cancer-fighting CAR-T cells to treat leukemia and lymphoma.

28 Sep 2018

Verastem Oncology selects US Bioservices to dispense COPIKTRA capsules

US Bioservices, a specialty pharmacy that is a part of AmerisourceBergen, today announced that it has been selected by Verastem OncologyTM to dispense COPIKTRA (duvelisib) capsules.

28 Sep 2018

Pfizer announces FDA approval of VIZIMPRO for first-line treatment of EGFR-mutated metastatic NSCLC

Pfizer Inc. today announced that the U.S. Food and Drug Administration has approved VIZIMPRO [vih-ZIM-pro] (dacomitinib), a kinase inhibitor for the first-line treatment of patients with metastatic non-small cell lung cancer with epidermal growth factor receptor exon 19 deletion or exon 21 L858R substitution mutations as detected by an FDA-approved test.

28 Sep 2018

FLX Bio treats first patient in its Phase 1/2 clinical trial of FLX475 for treating various advanced cancers

FLX Bio, Inc., a clinical-stage, biopharmaceutical company focused on the development of oral small-molecule drugs that target drivers of cancer and other immune-related disorders, today announced that the first patient has been treated in its Phase 1/2 clinical trial of FLX475 in patients with various advanced cancers. FLX475 is an oral, small molecule CCR4 antagonist that selectively inhibits migration of regulatory T cells into the tumor microenvironment.

27 Sep 2018

FDA lifts partial clinical hold that paused enrollment of new patients in tazemetosta clinical trials

Epizyme, Inc., a clinical-stage company developing novel epigenetic therapies, today announced the U.S. Food and Drug Administration has lifted the partial clinical hold that had paused U.S.-based enrollment of new patients in its tazemetostat clinical trials.

24 Sep 2018

ADCETRIS drug receives approval in Japan as frontline treatment option for Hodgkin lymphoma

Seattle Genetics, Inc. today announced that its collaborator, Takeda Pharmaceutical Company Limited, has received approval from the Japanese Ministry of Health, Labour and Welfare for ADCETRIS (brentuximab vedotin) in combination with doxorubicin, vinblastine and dacarbazine as a frontline treatment option for CD30-positive Hodgkin lymphoma patients in Japan.

24 Sep 2018

SNMMI announces recipients of 2018-2020 Wagner-Torizuka Fellowship

The Society of Nuclear Medicine and Molecular Imaging is pleased to announce the recipients of the 2018-2020 SNMMI Wagner-Torizuka Fellowship.

24 Sep 2018

Lymphoma News and Research

Further Reading

Merck presents KEYNOTE-057 trial results for patients with high-risk non-muscle invasive bladder cancer

FDA approves update to Rituxan label to include information on treatment of rare forms of vasculitis

Study highlights existence of barriers to early clinical trial access for adolescents and young adults

Takeda announces positive Phase 3 ALTA-1L data in first-line therapy for advanced ALK+ NSCLC

Survey finds high prevalence of HTLV-1 infection among teens and adults in Gabon

Women not warned about cancer associated with breast implants

New blood test for pediatric brain tumor patients offers safer approach than surgical biopsies

Phase 2 results on tazemetostat EZH2 inhibitor to be presented at ESMO 2018

'Supercharged' immune cells could help fight cancer

NCCN adds COPIKTRA capsules to NCCN Guidelines for follicular lymphoma

Researchers caution that expediting HLH treatment may miss underlying cancers

Phase 3 ECHELON-2 clinical trial evaluating ADCETRIS plus CHP meets primary endpoint

Cosmetic surgery providers' websites offer incomplete information to breast augmentation customers

Loyola announces plans to produce CAR-T cells for treating cancer

Verastem Oncology selects US Bioservices to dispense COPIKTRA capsules

Pfizer announces FDA approval of VIZIMPRO for first-line treatment of EGFR-mutated metastatic NSCLC

FLX Bio treats first patient in its Phase 1/2 clinical trial of FLX475 for treating various advanced cancers

FDA lifts partial clinical hold that paused enrollment of new patients in tazemetosta clinical trials

ADCETRIS drug receives approval in Japan as frontline treatment option for Hodgkin lymphoma

SNMMI announces recipients of 2018-2020 Wagner-Torizuka Fellowship

Everything you should know about lymphoma eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News